| Primary |
| Pneumonia |
22.3% |
| Sepsis |
8.7% |
| Hypertension |
5.9% |
| Pyrexia |
5.9% |
| Febrile Neutropenia |
5.5% |
| Meningitis |
5.1% |
| Disseminated Intravascular Coagulation |
4.7% |
| Infection |
4.3% |
| Toxic Skin Eruption |
4.2% |
| Insomnia |
4.0% |
| Gastritis |
3.7% |
| Asthma |
3.5% |
| Meningitis Bacterial |
2.9% |
| Pneumonia Aspiration |
2.9% |
| Adult T-cell Lymphoma/leukaemia |
2.7% |
| Bronchitis |
2.7% |
| Diabetes Mellitus |
2.7% |
| Post Procedural Infection |
2.7% |
| Urinary Tract Infection |
2.7% |
| Cerebral Infarction |
2.6% |
|
| Hepatic Function Abnormal |
18.0% |
| Renal Impairment |
8.4% |
| Interstitial Lung Disease |
7.8% |
| Liver Disorder |
6.6% |
| Pancytopenia |
6.0% |
| Drug Eruption |
5.4% |
| Platelet Count Decreased |
4.8% |
| Renal Failure Acute |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Thrombocytopenia |
4.2% |
| Depressed Level Of Consciousness |
3.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.6% |
| Exposure During Pregnancy |
3.0% |
| Liver Function Test Abnormal |
3.0% |
| Pyrexia |
3.0% |
| Septic Shock |
3.0% |
| Urticaria |
3.0% |
| Dermatitis Exfoliative |
2.4% |
| Hiccups |
2.4% |
| Oculomucocutaneous Syndrome |
2.4% |
|
| Secondary |
| Drug Use For Unknown Indication |
18.9% |
| Pneumonia |
15.4% |
| Sepsis |
7.7% |
| Prophylaxis |
5.2% |
| Pyrexia |
5.1% |
| Product Used For Unknown Indication |
4.9% |
| Febrile Neutropenia |
4.8% |
| Hypertension |
4.7% |
| Adult T-cell Lymphoma/leukaemia |
4.4% |
| Infection |
4.2% |
| Disseminated Intravascular Coagulation |
3.8% |
| Infection Prophylaxis |
3.8% |
| Urinary Tract Infection |
2.6% |
| Pyelonephritis |
2.3% |
| Fungal Infection |
2.3% |
| Constipation |
2.2% |
| Anaesthesia |
2.0% |
| Antifungal Prophylaxis |
1.9% |
| Bronchopulmonary Aspergillosis |
1.9% |
| Cerebral Infarction |
1.8% |
|
| Renal Impairment |
10.6% |
| White Blood Cell Count Decreased |
8.3% |
| Renal Failure |
7.3% |
| Interstitial Lung Disease |
6.9% |
| Hepatic Function Abnormal |
6.4% |
| Enterocolitis Haemorrhagic |
6.0% |
| Thrombocytopenia |
6.0% |
| White Blood Cell Count Increased |
5.5% |
| Pneumonia |
5.0% |
| Sepsis |
5.0% |
| Liver Disorder |
4.6% |
| Pyrexia |
4.6% |
| Lung Disorder |
4.1% |
| Acute Generalised Exanthematous Pustulosis |
3.2% |
| Platelet Count Decreased |
3.2% |
| Refusal Of Treatment By Patient |
3.2% |
| Respiratory Failure |
2.8% |
| Urinary Tract Infection |
2.8% |
| Renal Disorder |
2.3% |
| Shock |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.7% |
| Drug Use For Unknown Indication |
21.9% |
| Prophylaxis |
8.9% |
| Pneumonia |
8.3% |
| Infection Prophylaxis |
4.9% |
| Hypertension |
3.6% |
| Nutritional Support |
2.9% |
| Sepsis |
2.9% |
| Pyrexia |
2.7% |
| Infection |
2.6% |
| Stem Cell Transplant |
2.5% |
| Pneumonia Aspiration |
2.3% |
| Myelodysplastic Syndrome |
2.1% |
| Cancer Pain |
2.0% |
| Immunosuppressant Drug Therapy |
1.8% |
| Premedication |
1.7% |
| Sedation |
1.7% |
| Colon Cancer |
1.7% |
| Constipation |
1.5% |
| Rheumatoid Arthritis |
1.4% |
|
| White Blood Cell Count Decreased |
17.3% |
| Sepsis |
10.4% |
| Pyrexia |
7.6% |
| Renal Impairment |
7.6% |
| Pneumonia |
6.9% |
| Interstitial Lung Disease |
5.8% |
| Platelet Count Decreased |
5.0% |
| White Blood Cell Count Increased |
5.0% |
| Thrombocytopenia |
4.1% |
| Renal Failure |
3.5% |
| Multi-organ Failure |
3.2% |
| Pneumonia Aspiration |
3.0% |
| Death |
2.8% |
| Pancytopenia |
2.8% |
| Respiratory Failure |
2.8% |
| Stomatitis |
2.8% |
| Liver Disorder |
2.6% |
| Rhabdomyolysis |
2.4% |
| Pleural Effusion |
2.2% |
| Septic Shock |
2.2% |
|
